Swiss food conglomerate Nestle is reportedly expanding its skincare portfolio after acquiring various injectable treatment patents in a $1.4 billion deal.
Reports say Nestle acquired the rights for various wrinkle treatments from Valeant Pharmaceuticals.
While the deal allows Nestle to own the rights to treatments acquired when it fully took over its joint venture with Galderma, the transaction poses benefits for Valeant, as well. According to reports, the sale unloads a possible antitrust hurdle for Valeant, which is looking to acquire US Botox maker Allergan.
Some analysts, however, doubt that the acquisition will be as beneficial to Nestle as intended. The company has been looking for years to expand from a confectionary company into a global healthcare and nutrition brand; some experts, reports say, doubt that winkle treatment fits under that market.
Full content: International Business Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
T-Mobile’s Acquisition of Ka’ena Corporation Receives FCC Approval
Apr 26, 2024 by
CPI
UK Regulator Announces Two New Senior Executive Appointments
Apr 26, 2024 by
CPI
Paramount Global and Skydance Media Near Merger Deal, Eyeing CEO Change
Apr 26, 2024 by
CPI
BHP Unveils £31bn Mining Megamerger Proposal with Anglo American
Apr 25, 2024 by
nhoch@pymnts.com
ByteDance Prefers Shutdown Over Sale of TikTok Amid US Ban Threats
Apr 25, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI